Accurate lung model will allow asthmatics to breathe easy

by Susanna Wolz

Curtin University researchers have taken large strides towards revolutionising drug delivery for asthmatics and people with lung diseases, potentially saving thousands of lives and millions of dollars.

Associate Professor Ben Mullins from the School of Public Health and lead researcher on the project, said were the most common causes of death in people over 65 years.

"Chronic Obstructive Pulmonary Disease (COPD) and pneumonia are two of the top five killers of the elderly, with COPD claiming one patient every 10 seconds," Associate Professor Mullins said.

"Asthma affects approximately 15 per cent of the Australian population and $358 million is spent on alone per year, yet more than 95 per cent of it is wasted.

"This is because it is not delivered to the appropriate target area of the airway and the main reason for this is that models to accurately predict the capture of particles on moving surfaces in unsteady flow (such as human airways), do not exist yet.

"In response to this, we developed the most advanced and physiologically realistic lung model to simulate airflow, which will revolutionise aerosol drug delivery (such as Ventolin inhalers) and also assess exposure to .

"This research is the first of its kind and allows us to get better information on what is happening at highly localised regions in the lung. This will, in turn, allow us to better target drug delivery to where it is needed most.

"This will be highly beneficial to asthmatics, people with COPD, and patients with lung disease, as well as all groups exposed to in the atmosphere.

This is part of a larger project which aims not only to design better aerosol , but to develop tools to predict surgical outcomes on a patient-by-patient basis to better inform surgeons prior to invasive lung surgery," Associate Professor Mullins said.

The paper, titled 'The influence of moving walls on respiratory aerosol deposition modelling' has been published in the Journal of Aerosol Science.

More information: doi: 10.1016/j.jaerosci.2013.05.006.

add to favorites email to friend print save as pdf

Related Stories

US panel backs inhaler drug for lung disease

Apr 17, 2013

A panel of U.S. respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease.

Researchers explore PKC role in lung disease

Feb 25, 2013

New research examines the role of PKC in airway smooth muscle contraction and raises the possibility that this enzyme could be a therapeutic target for treating asthma, COPD, and other lung diseases.

Recommended for you

Sri Lanka celebrates two years without malaria

1 hour ago

Sri Lanka has not reported a local case of malaria since October 2012, according to the Sri Lankan Anti-Malarial Campaign. If it can remain malaria-free for one more year, the country will be eligible to apply to the World ...

Poll: Many doubt hospitals can handle Ebola

4 hours ago

A new poll finds most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient.

Number of Ebola cases nears 10,000

5 hours ago

The number of people with Ebola is set to hit 10,000 in West Africa, the World Health Organization said, as the scramble to find a cure gathered pace.

'Breath test' shows promise for diagnosing fungal pneumonia

5 hours ago

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the ...

User comments